TaiGen links with Zhejiang in cross-strait China deal for nemonoxacin
This article was originally published in Scrip
Executive Summary
In a sign of the steady thawing, at least in business relations, between mainland China and Taiwan, the Hangzhou-based Zhejiang Medicine Company (ZMC) has signed a deal with TaiGen Biotechnology in Taipei for what they describe as the world's first broad-spectrum, non-fluorinated quinolone antibiotic in development for respiratory infections.